A Food and Drug Administration advisory committee has backed Galleri, a blood test designed to screen for up to 50 types of cancer, according to The Washington Post and USA Today.
The committee was split on how well the test performs, the Post reported. The test's final approval now rests with the FDA, which has not yet issued a decision.
USA Today described the test as controversial, without detailing the specific concerns raised by the panel. MedPage Today, a center-leaning outlet, also covered the FDA advisors' review but did not provide further detail on their assessment in the material available.
How each side covered it
Left
- Left-leaning outlets reported that an FDA advisory panel backed the Galleri multi-cancer blood test despite mixed views on its effectiveness.
- Coverage highlighted that the test screens for up to 50 cancers but remains controversial among experts.
- Reports noted the FDA has not yet made a final decision on the test's approval.
“A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works.” — The Washington Post
Center
- Center outlets framed the story as a quiz-style question asking whether FDA advisors actually supported the cancer detection blood test.
- Coverage from MedPage Today targeted a medical professional audience, testing readers' knowledge of the panel's decision.
“Did FDA Advisors Support a Cancer Early-Detection Blood Test?” — MedPage Today
Questions readers ask
What happened with the Galleri cancer blood test?
A Food and Drug Administration advisory committee backed the Galleri blood test, which screens for signs of up to 50 cancers, but the panel was split on how well the test works, according to The Washington Post and USA Today.
Has the FDA approved the Galleri test?
No. The FDA advisory committee's support is not a final decision; the test is still awaiting a ruling from the FDA itself, according to The Washington Post.
Why is the Galleri test considered controversial?
USA Today described the test as controversial, and The Washington Post reported that the FDA advisory committee was divided on how well the test performs, though specific reasons for the disagreement were not detailed in the available material.
What happens next for the Galleri blood test?
The test now awaits a final decision from the Food and Drug Administration following the advisory committee's split vote of support, according to The Washington Post.
Sources · 3 outlet reports
- The Washington PostLeft-leaningOne blood test could screen you for 50 cancers. Here’s why it’s controversial.
- USA TodayLeft-leaningA controversial, cancer-detecting blood test just got backed by key FDA panel
- MedPage TodayCenterDid FDA Advisors Support a Cancer Early-Detection Blood Test?